Prevalence of adverse events following T-cell engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T-cell therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC): A meta-analysis.

Le résumé fourni par la source

128 Background: T-cell engaging bsAbs and CAR T-cell therapy have shown exceptional success in treating multiple hematologic malignancies. More recently, bsAbs have been FDA-approved to treat uveal melanoma and small cell lung cancer, demonstrating proof-of-concept for immune therapies beyond checkpoint inhibition to effectively treat solid tumors. bsAbs and CAR-T therapies are presently undergoing evaluation in trials for patients with mCRPC. Despite early successes with these classes of therapy, there are multiple ongoing challenges including dose-limiting toxicity, ‘on-target, off-tumor’ toxicity, and immune-effector cell related toxicity. This systematic review analyzes publicly available safety derived from ongoing clinical trials. Methods: An electronic systematic search through PubMed, CINHAL, Scopus, and Ovid was done to identify phase I/II clinical trials evaluating bsAbs or CAR-T therapy in patients with mCRPC reported prior to 9/30/2024. Treatment-related adverse events (TRAE) were collected, focusing on prevalence in bsAbs versus CAR-T. A random effects model was used for analysis. Results: Eleven trials with 511 patients evaluated bsAbs, and 5 trials with 55 patents studied CAR-T therapies. Mean patient age was 67 years [95% CI: 63, 71]. Cytokine release syndrome (CRS) occurred in 49% [24, 75] of patients; 53% [17, 86] on bsAbs compared to 43% [28, 59] on CAR-T. Only 4% [2, 7] of patients had CRS grade ≥3; 14% [2, 43] on CAR-T compared to 3% [2, 6] on bsAbs (p=0.05). Neurologic TRAEs occurred in 11% [3, 31] of patients; 39% [22, 60] on CAR-T compared to 5% [2, 13] on bsAbs (p= <0.01). Hematologic TRAEs occurred in 38% [14, 71] of patients; 34% [8, 75] on CAR-T compared to 43% [9, 86] on bsAbs. Hepatic TRAEs occurred in 31% [12, 59] of patients; 25% [12, 44] on CAR-T compared to 39% [9, 81] on bsAbs (p= 0.55). However, 8% of patients [3, 20] had grade ≥3 hepatic TRAEs, with 21% [5, 51] on CAR-T versus 5% [2, 10] on bsAbs (p=0.03). Musculoskeletal/dermatologic TRAEs were seen in 30% of patients [24, 37]; 30% [24, 38] on bsAbs and 29% [8, 58] on CAR-T (p=0.89). Renal TRAEs occurred in 15% [10, 23] of patients; 21% [5, 51] on CAR-T compared to 14% [8, 24] on bsAbs (p= 0.50). Gastrointestinal TRAEs were reported in 18% [10, 33] of patients; 14% [2, 42] on CAR-T compared to 19% [9, 36] on bsAbs (p= 0.69). Conclusions: In patients with mCRPC, bsAbs and CAR-T therapies produce similar hematological, musculoskeletal/dermatologic, renal and gastrointestinal TRAE rates. However, significantly higher rates of all-grade neurologic, grade ≥3 CRS and grade ≥3 hepatic TRAEs are reported with CAR-T therapy. These data highlight the need to appreciate the differences in toxicity profiles for these two classes of therapy and to practice appropriate vigilance during treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.